StockData

Ametek vs Keysight Technologies

AME and KEYS side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AME and KEYS compare

Ametek and Keysight Technologies are about the same size, with market caps of $55.3B and $52.3B.

On earnings, Ametek is cheaper: it trades at 35.3× trailing earnings, against 42.1× for Keysight Technologies.

Keysight Technologies grew revenue faster over the last twelve months (25.5% versus 12.7% for Ametek).

Ametek keeps more of each dollar of sales as profit, with a net margin of 20.0% compared with 19.1% at Keysight Technologies.

Ametek pays a dividend yielding 0.55%; Keysight Technologies does not pay one.

Ametek scores higher on the StockData Score (18 against 14 for Keysight Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMEKEYS
Size and price
Market cap$55.3B$52.3B
Share price$241.12$307.20
Change, 1 year30.9%80.2%
Change, 5 years71.1%67.2%
Beta (5Y)0.891.38
Employees13K17K
StockData Score
Total score18 (better)14
Valuation score11
Growth score3 (better)2
Performance score55
Health score66
Dividend score3 (better)0
Valuation
P/E35.3× (better)42.1×
P/S7.0× (better)7.9×
P/B4.9× (better)8.0×
EV/EBITDA23.1× (better)39.2×
P/FCF30.3× (better)35.6×
PEG4.15–
FCF yield3.3% (better)2.8%
Fair value$207.73$245.85
Margin of safety−16.1% (better)−25.0%
Growth
Revenue growth (TTM)12.7%25.5% (better)
Revenue growth, 5Y average10.3% (better)5.0%
Net income growth (TTM)9.6%132% (better)
EPS growth (TTM)10.1%132% (better)
EPS growth, 5Y average11.2% (better)8.2%
Profitability
Gross margin36.4%64.7% (better)
Operating margin25.9% (better)20.3%
Net margin20.0% (better)19.1%
FCF margin23.2% (better)22.3%
Return on equity14.6%20.6% (better)
Return on invested capital13.7%21.3% (better)
Financial health
Debt / equity0.18 (better)0.38
Net debt / EBITDA0.63 (better)−0.07
Interest coverage21.1× (better)12.3×
Current ratio1.212.02 (better)
Altman Z-score8.23 (better)8.01
Piotroski F-score8 (better)6
Dividends and buybacks
Dividend yield0.55%–
Payout ratio18.9%–
Buyback yield0.80%1.2% (better)
Shareholder yield1.4% (better)1.2%
Ownership
Held by institutions89.7%90.6%
Held by insiders0.37%0.72%
Insider net buying, 12 months−$28.5M (better)−$32.5M
Superinvestors holding12 (better)
Short interest, % of float1.7%1.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.